Results 101 to 110 of about 156,482 (265)

CCL3 and IL‐7 Synergistically Enhance CAR‐T Efficacy in Solid Tumors

open access: yesAdvanced Science, EarlyView.
Synergistic delivery of CCL3 and IL‐7 by CAR‐T cells overcomes the immunosuppressive tumor microenvironment by enhancing cell infiltration, survival, and local immune reprogramming. This also establishes positive feedback that amplifies anti‐tumor activity and memory responses in both CAR‐T and endogenous T cells, presenting a robust therapeutic ...
Huanpeng Chen   +12 more
wiley   +1 more source

Tumor‐Specific Delivery of CD28 siRNA via Lyso‐PC C‐16 Modified Lipid Nanoparticles Overcomes Anti‐PD‐1 Resistance by Remodeling Tumor Microenvironment

open access: yesAdvanced Science, EarlyView.
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai   +12 more
wiley   +1 more source

A Brain‐Penetrant Nanobody Reveals GSK3β‐Driven Proline‐Directed Phosphorylation as a Master Regulator of Ischemic Neurodegeneration

open access: yesAdvanced Science, EarlyView.
A brain‐targeted nanoparticle enables delivery of a therapeutic nanobody (Nb.29E9) that inhibits pathogenic GSK3β signaling. This intervention restores AMPK/mTORC1/TGFβ homeostasis, attenuates neuroinflammation and oxidative stress, and promotes long‐term functional recovery after ischemic stroke.
Lan Li   +14 more
wiley   +1 more source

PRMT9 Aggravated Dopaminergic Neurodegeneration in Parkinson's Disease Model by Facilitating the Degradation of DUSP26 and Inducing Mitochondrial Dysfunction

open access: yesAdvanced Science, EarlyView.
In the pathological state of PD induced by MPP+, the upregulated PRMT9 in dopaminergic neurons translocates into mitochondrion and interacts with DUSP26 and catalyzes its arginine methylation, leading to the ubiquitin‐proteasomal degradation of DUSP26 mediated by Trim32.
Tengfei Liu   +13 more
wiley   +1 more source

Targeting DNGR‐1 with Fangchinoline Elevates Dendritic Cell Antigen Cross‐Presentation‐Mediated Antitumor Immunity in Melanoma

open access: yesAdvanced Science, EarlyView.
Fangchinoline is identified as a small‐molecule DNGR‐1 modulator that enhances dendritic‐cell cross‐presentation of tumor antigens. By engaging DNGR‐1 and activating Syk–Nox2 signaling, it promotes phagosomal ROS, antigen escape, MHC‐I presentation, and CD8+ T‐cell priming, thereby strengthening antitumor immunity and sensitizing tumors to PD‐1 ...
Yuan Liao   +19 more
wiley   +1 more source

Designer Dynamic DNA Nanoaggregate in Living Cell for Mitochondrial Energy Restriction

open access: yesAdvanced Science, EarlyView.
This study presents the Tech‐tetrahedron, a designer dynamic DNA nanoaggregate engineered for precise mitochondrial energy restriction. Its trinity‐functionalized design integrates navigable unit, telomerase‐activated latch, and self‐assembly module.
Ruijia Deng   +12 more
wiley   +1 more source

Single‐Cell Reveal GALNT7‐Dependent Ferroptosis Suppression as a Mechanism of Immunotherapy Resistance in Non‐Small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
Integrated clinical and mechanistic analyses identify GALNT7 as a ferroptosis‐suppressive regulator associated with immunotherapy resistance in non‐small cell lung cancer. GALNT7 depletion promotes lipid peroxidation, mitochondrial dysfunction, and ferroptosis, enhances CD8+ T‐cell activation and IFN‐γ production, and sensitizes tumors to PD‐1 blockade,
Jiadi Gan   +11 more
wiley   +1 more source

Membrane Fusion‐Mediated Cytosolic Delivery of Threose Nucleic Acids via Homotypic Nanoparticles Overcomes Drug Resistance in Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
This study introduces a biomimetic “nanofusion” platform that integrates the biostability of threose nucleic acids (TNA) with homotypic cell‐membrane cloaking to combat drug‐resistant TNBC. By leveraging a non‐canonical membrane‐fusion pathway for direct cytosolic delivery, the platform bypasses endosomal sequestration. To achieve potent AKT2 silencing
Wei Zheng   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy